MARKET

GHRS

GHRS

Gh Research Plc
NASDAQ
28.22
+2.88
+11.37%
After Hours: 27.75 -0.47 -1.67% 19:28 06/26 EDT
OPEN
25.08
PREV CLOSE
25.34
HIGH
28.32
LOW
25.08
VOLUME
275.64K
TURNOVER
--
52 WEEK HIGH
28.32
52 WEEK LOW
11.32
MARKET CAP
1.93B
P/E (TTM)
-31.0280
1D
5D
1M
3M
1Y
5Y
1D
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM
TipRanks · 1d ago
GH Research shareholders re-elect directors at annual general meeting
PUBT · 1d ago
Weekly Report: what happened at GHRS last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at GHRS last week (0608-0612)?
Weekly Report · 06/15 09:23
Weekly Report: what happened at GHRS last week (0601-0605)?
Weekly Report · 06/08 09:22
GH Reports Primary Endpoint Met In Phase 2a For GH001 In Treating Post-Partum Depression
NASDAQ · 06/05 10:26
Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003
TipRanks · 06/04 15:00
GH Research announces publication of Phase 2a results for mebufotenin
TipRanks · 06/04 14:40
More
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.

Webull offers GH Research PLC stock information, including NASDAQ: GHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GHRS stock methods without spending real money on the virtual paper trading platform.